Publications
277
Citations
20,565
Est. group size
~7
Recurring co-author estimate
Active years
40
Publishing since 1987
Typically publishes in teams of ~19 · 9% small-team papers (≤3 authors) · across 25 venues
- Efficacy and safety of engineered TCR-T cell therapy (afami-cel, lete-cel) in pediatric synovial sarcoma.
Journal of Clinical Oncology · 2026
- Pooled analyses of clinical outcomes with afamitresgene autoleucel (afami-cel) in metastatic synovial sarcoma.
Journal of Clinical Oncology · 2026
- Measured intrapatient radiomic variability as a predictor of treatment response in multi-metastatic soft tissue sarcoma patients
Scientific Reports · 2025
- Identifying Adolescent and Young Adults’ Preferences for Oncology Symptom Management Clinical Trial Participation
Cancer Nursing · 2025
- ETCTN 10563: A phase I study of peposertib and liposomal doxorubicin for advanced or metastatic leiomyosarcoma and other sarcomas.
Journal of Clinical Oncology · 2025
- Long-Term Survival of Patients with Advanced/Metastatic Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Who Received the T-Cell Receptor T-Cell Therapy, Afamitresgene Autoleucel, in the Phase 2 Spearhead-1 Trial
Transplantation and Cellular Therapy · 2025
- Measured intrapatient radiomic variability as a predictor of treatment response in multi-metastatic soft tissue sarcoma patients
medRxiv · 2025
- 1309 Measured intrapatient radiomic variability as a predictor of treatment response in multi-metastatic patients
Radiotherapy and Oncology · 2025
- Improved detection of circulating tumor DNA in patients with leiomyosarcoma with fragment size restriction.
Journal of Clinical Oncology · 2025
- Performance status and quality of life in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma receiving afamitresgene autoleucel
ESMO rare cancers. · 2025
- Palbociclib in Patients With Soft Tissue Sarcoma With <i>CDK4</i> Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study
JCO Precision Oncology · 2024
- Radiomic-based prediction of lesion-specific systemic treatment response in metastatic disease
Computerized Medical Imaging and Graphics · 2024
- Exploring Adolescent and Young Adult Cancer Survivors’ Experience with Cancer Treatment-Related Symptoms: A Qualitative Analysis of Semi-Structured Interviews
Journal of Adolescent and Young Adult Oncology · 2024
- 140TiP Brightline-4: A phase III open-label, single-arm, multicentre study to assess the safety and efficacy of brigimadlin (BI 907828), an MDM2-p53 antagonist, in patients with treatment-naïve or pretreated advanced dedifferentiated liposarcoma
ESMO Open · 2024
- Abstract CT288: Brightline-4: A phase 3 open-label, single-arm, multicenter study to assess the safety and efficacy of brigimadlin (BI 907828) treatment in patients with treatment-naïve or pretreated advanced dedifferentiated liposarcoma
Cancer Research · 2024
- Journal of Clinical Oncology×44
- Annals of Oncology×9
- Journal of the National Comprehensive Cancer Network×8
- The Lancet Oncology×4
- Clinical Cancer Research×4
- Kelly Scheu
Medicine · University of Michigan
- Rashmi Chugh
Medicine · University of Michigan
- Denise K. Reinke
Medicine · University of Michigan
- David A. Liebner
Medicine · The Ohio State University
- Raphael E. Pollock
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile